Final Program - American Society of Gene & Cell Therapy

Program Schedule, Wednesday, May 15, 2013
Manfred Schmidt, PhD
Clonality and Biosafety Aspects of Illegitimate Integration
Integrating retroviral vectors have been used successfully in clinical applications. With the occurrence of integration associated
severe side effects, enhanced efforts have been set for the clinical translation of integrase deicient viral vectors to guarantee
improved biosafety. In this presentation, the focus is set on studies performed for assessing frequency, proile and mechanisms of
(illegitimate) integration.
Scott H. Robbins, PhD
Development of an ID-LV as a Gene Delivery Platform for Immunotherapy Applications
One of the most fundamental challenges for the design of next generation vaccines is the generation of antigen-speciic CD8 T
cell responses. The direct administration of lentivector-based vaccines genetically encoding antigen is proving to be an effective
approach to elicit CD8 T cell responses in pre-clinical animal models. The ability to alter the tropism of lentiviral vectors via
pseudotyping and other mechanisms makes them attractive as a platform technology on which to base product candidates for
clinical applications such as antigen-directed immunotherapy and vaccines. Examples of the functionality of integration-competent
and -deicient lentiviral vectors as antigen delivery vehicles in pre-clinical settings will be provided as well as an example of the
design of a dendritic cell-directed integration-deicient lentiviral vector that is currently under development as an antigen-directed
cancer immunotherapy (a “cancer vaccine”).
Wednesday, May 15, 2013
Oral Abstract Session 130
3:15 pm - 5:15 pm
ROOM: BALLROOM A
AAV Vector Development & Application
CO-CHAIRS: Mavis Agbandje-McKenna, PhD and Hiroyuki Nakai, MD, PhD
(Abstracts 1 through 8; see page 87)
Oral Abstract Session 131
3:15 pm - 5:15 pm
ROOM: BALLROOM B
Cancer - Immunotherapy I
CO-CHAIRS: Malcolm K. Brenner, MD, PhD and John J. Nemunaitis, MD
(Abstracts 9 through 16; see pages 87-88)
Oral Abstract Session 132
3:15 pm - 5:15 pm
ROOM: 150 DEFG
Cancer - Oncolytic Viruses
CO-CHAIRS: David Kirn, MD and Stephen J. Russell, MD, PhD
(Abstracts 17 through 24; see page 88)
Oral Abstract Session 133
3:15 pm - 5:15 pm
ROOM: BALLROOM C
Advancing the Science of Gene Therapy for Hematologic Diseases
CO-CHAIRS: Arnab Ghosh, MD, PhD and Donald B. Kohn, MD
(Abstracts 25 through 32; see pages 88-89)
Final Program SALT LAKE CITY, UTAH May 15–18, 2013
43